Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Drugs After Age 80: A Matched Cohort of 11,464 Pairs With Diabetes

In 11,464 matched pairs aged 80 or older with type 2 diabetes, GLP-1 use was associated with lower mortality than DPP-4 inhibitor use.

Editorial profile: Carla MedinaBuy This GLP Editorial Team3 min read
Mean age 81.6 · 11,464 matched pairsdeath (any cause)0.82cardiovascular events0.86kidney events0.86hospitalization0.91heart failureno significant differenceHazard ratios from a matched cohort.

Studies of who receives GLP-1 treatment examine access across age groups. This study instead compared health outcomes for people aged 80 and older who started one of two diabetes treatments [1].

What the study compared

Researchers matched 11,464 pairs of people with type 2 diabetes who started either a GLP-1 receptor agonist or a DPP-4 inhibitor. Follow-up extended up to five years [1].

Death from any cause was recorded in 14.5% of GLP-1 users and 19.1% of DPP-4 users. The estimated hazard ratio was 0.82 (95% CI 0.77 to 0.88). The hazard ratios for major cardiovascular and major kidney events were each 0.86.

How to read the safety findings

Research on fractures in another GLP-1 cohort examines a different population. This study found no statistically clear difference in fracture or heart failure hazards [1].

Matching accounted for measured characteristics. Unmeasured factors, such as functional status or the reasons one treatment was chosen, could still affect the results. The study applies most directly to older adults starting treatment for type 2 diabetes.

Frequently asked

How did mortality differ in this cohort?
The estimated mortality hazard was lower among GLP-1 users (hazard ratio 0.82). This observational comparison cannot establish cause.
Were heart failure and fractures less common?
The study found no statistically clear difference between the two groups for either outcome.

Sources

  1. [1] Chen JC, Fang YW, Liu YF, Chen MT, Tsai MH (2026). GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes Journal of the American Geriatrics Society. PMID 41132144

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence